AB SCIEX, Genedata and LECO Announce Partnership
Article Jul 02, 2013
AB SCIEX, Genedata, and LECO have announced a technology partnership that will deliver a collaborative software system, which will enable metabolomics researchers to comprehensively process and analyze experimental data across different GC/MS and LC/MS platforms. LECO Corporation, a global leader in accurate mass technologies and GC/MS instrumentation, is offering combined solutions with both AB SCIEX, a global leader in LC/MS technology, and Genedata, a global leader in advanced software solutions for drug discovery and life science research. The companies are collaborating to provide a seamless solution to extract valuable biological information from high fidelity LC and GC data. The solution will give metabolomics researchers the ultimate tool for truly comprehensive metabolomics investigations. The partnership announcement was made at the 9th Annual Conference of the Metabolomics Society (July 1-4).
"The ability to bring data from different vendors and technologies onto a single platform, which can process and merge data for maximum biological inference, is where the industry needs to be to effectively evaluate the entire metabolome," said Dr. Vladimir V. Tolstikov, Scientist, Tailored Therapeutics of Eli Lilly and Company.
The close collaboration of the three companies has resulted in the latest version of Genedata Expressionist® MSX software, developed for metabolomics experiments performed with LECO and AB SCIEX MS systems. Genedata Expressionist MSX, which is compatible with other data formats and technologies as well, is a comprehensive, end-to-end solution for the analysis of mass spectrometry data generated in metabolomics experiments. The software can be downloaded directly via the Internet for immediate installation.
Untargeted metabolomics approaches are allowing previously unreported insights into the pathogenesis of disease. However, identifying the large numbers of unknown and structurally diverse metabolites typically present in biological samples has proven to be a major bottleneck. Fortunately, recent advances in technology and software are helping to overcome this challenge.READ MORE
The UK’s national health system needs to take a hard look at their priorities and procedures to ensure that rapid advances in molecular diagnostics in lung cancer are translated into a practical service for all patients, according to a report launched at the British Thoracic Oncology Group Annual Conference.READ MORE
First developed in the 1970s, recent developments are making microflow liquid chromatography techniques more robust – enticing researchers to revisit the opportunities it offers for more sensitive, high-throughput analyses requiring smaller sample volumes than standard flow techniques.READ MORE